ASH 2022 | The safety and efficacy of belantamab mafodotin in AL amyloidosis
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, outlines the rationale for using belantamab mafodotin in relapsed/refractory (R/R) light chain (AL) amyloidosis, discussing the efficacy and toxicity of this agent. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Belantamab mafodotin is a BCMA monoclonal conjugated to a toxin. In AL amyloidosis, the plasma cells will express BCMA in a very similar way to plasma cells with multiple myeloma, and therefore belantamab would have a role in amyloidosis.
We reported a small retrospective series of belantamab in 10 patients, showing very good responses in two-thirds of the patients treated with belantamab, including complete responses in multiply relapsed patients...
Belantamab mafodotin is a BCMA monoclonal conjugated to a toxin. In AL amyloidosis, the plasma cells will express BCMA in a very similar way to plasma cells with multiple myeloma, and therefore belantamab would have a role in amyloidosis.
We reported a small retrospective series of belantamab in 10 patients, showing very good responses in two-thirds of the patients treated with belantamab, including complete responses in multiply relapsed patients. There is a European study looking at belantamab prospectively in patients with relapsed/refractory amyloidosis.
The challenge with belantamab, of course, is that corneal toxicity is a major issue. Because amyloidosis has slow disease space, we can dose belantamab less frequently, without the disease progressing. It is used without corticosteroids, which are a huge challenge in amyloidosis. It is used without any other chemotherapy agents, and therefore it is one of those agents which has a potential to be a good treatment for amyloidosis, although there are challenges in dealing with ocular toxicity.
Read more...
Disclosures
Janssen: Honoraria, Other: Travel Support; Attralus: Honoraria; Takeda: Other: Travel Support; Alexion: Honoraria, Other: Travel Support; GSK: Honoraria.
